Aiforia vs Mindpeak
Both are CE marked algorithm vendors with no FDA clearance, both grade A on AI centrality, and both are assistive by design, so the choice is breadth versus depth and where the evidence comes from. If you need broad multi tumor CE coverage or want to build your own models, start with Aiforia. If you want deep, independently validated breast biomarker quantification embedded in a platform you may already run, start with Mindpeak. Aiforia sells clinical suites across five tumor types plus lymph node and offers a model building engine, but its evidence is largely adoption signal and research. Mindpeak concentrates on breast immunohistochemistry, the highest volume workload in European pathology, and is the one vendor in this group whose validation is genuinely independent rather than vendor run.
- Breadth: CE-IVD clinical suites across breast, prostate, lung, colorectal, and gastric cancer plus lymph node metastasis, versus Mindpeak's concentration in breast immunohistochemistry.
- A build your own capability: the Aiforia Create platform lets pathologists develop their own models, which has produced a large body of research use models, with no equivalent from Mindpeak.
- Vendor stability visibility: its Helsinki listing forces financial disclosure that most private competitors in this group do not provide.
- The only genuinely independent evidence in this group: third party studies, including work by Abele and colleagues on Ki-67, ER, and PR and a concordance study at Aga Khan University Hospital, rather than vendor run validation.
- Depth where the volume is: breast immunohistochemistry covering HER2, ER, PR, and Ki-67, with a cell level classification distinguishing tumor from non tumor structures.
- Lower adoption friction: distributed inside PathAI's AISight since 2025, so for laboratories already on that platform adoption is algorithm selection rather than an integration project.
Side-by-Side
| Axis | A Aiforia |
M Mindpeak |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both are CE-IVD only with no FDA clearance, so neither is deployable for US clinical diagnosis without a separate path, and both report evidence as concordance and efficiency rather than patient outcome. Neither publishes pricing, a security attestation, or demographic subgroup analysis. Aiforia's headline efficiency figures, for example up to 40 percent pathologist time saved on lymph node review, are vendor quoted and not independently verified, and its integration depth is asserted through partnerships such as Siemens Healthineers rather than an enumerated connector list. Mindpeak's clinical coverage is narrower than its full product list suggests, since its prostate and other assays are research use only, and because its algorithms run inside a third party platform, data residency and stewardship follow the host rather than Mindpeak.